Generated by Codex with GPT-5

This summary covers The Economist’s June 20th, 2026 Science & technology / Well Informed article listed in the contents as A cancer breakthrough and published under the headline Has one of cancer's master switches been found?.

Pancreatic cancer is one of medicine’s hardest targets: it is aggressive, often detected late and usually resists immunotherapy. The article argues that a new drug, daraxonrasib, matters because it has produced a rare and meaningful gain against that disease while also pointing toward a broader class of cancer treatments.

More Time Against A Brutal Disease

Daraxonrasib, developed by Revolution Medicines, is not presented as a cure. Its immediate promise is narrower but still important. In clinical trials, it nearly doubled median survival for pancreatic-cancer patients from 6.7 months to 13.2 months. For a cancer in which many patients do not survive a year after diagnosis, buying extra months can be a major clinical advance.

The caveat is that targeted cancer drugs often lose power as tumours evolve resistance. The article therefore frames daraxonrasib less as a final answer than as a new tool that could be combined with chemotherapy, immunotherapy or future targeted drugs. It may also move quickly through American approval and could eventually become a first-line treatment rather than a fallback after chemotherapy.

Why KRAS Matters

The deeper significance lies in the drug’s target: KRAS, a protein that helps regulate cell division. When KRAS is mutated, it can become stuck in an active state, sending cells a constant signal to multiply. That is a basic mechanism behind many cancers, and it is especially common in pancreatic tumours.

For decades KRAS was considered almost impossible to drug because its shape offered few obvious places for medicines to bind. Daraxonrasib shows that this barrier is no longer absolute. By inhibiting KRAS, it may not only slow tumour growth directly but also change the tumour environment in ways that make immune-based treatments more effective.

A Wider Opening

The article’s larger point is that success against pancreatic cancer could reverberate across oncology. KRAS mutations also drive some colorectal, lung, endometrial, small-bowel and stomach cancers. KRAS itself belongs to the wider RAS family of cancer-linked genes, whose mutations are found in roughly a fifth of all cancers, representing millions of cases each year.

That does not mean one drug will treat all those diseases. Different tumours use related biological pathways in different ways, and future drugs will need to be more refined. But daraxonrasib suggests that a long-sought molecular switch can be reached after all. Its importance is therefore both practical and symbolic: it may extend lives now, and it gives researchers a stronger route into cancers once thought beyond the reach of targeted medicine.